Epigenomics Ag (EPGNY) 25.2600 $EPGNY
World Cancer Diagnostic Testing Markets Report 2016
M2 - Wed Jan 20, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/xg6l8p/cancer_diagnostic) has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Partial List - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Ambrilia Biopharma, Inc. - AMDL, Inc. - Asuragen, Inc. - Aureon Laboratories, Inc. - Bard Diagnostics, Inc. - Beckman, Dickinson and Company (BD) Diagnostics - TriPath - Beckman Coulter, Inc. - Biocode S.A. - BioCurex - Biomedical Diagnostics - Biomerica - bioMerieux - BioModa, Inc. - Bruker Daltonics - Byk Gulden - Cepheid - Clarient, Inc. - Correlogic Systems, Inc. - CytoCore (formerly Molecular Diagnostics, Inc.) - Cytogen Corporation (now EUSA Pharma) - diaDexus, Inc. - DiagnoCure, Inc. - Diagnostic Automation / Cortez Diagnostics, Inc. - DRG International, Inc. - Eisai Co., Ltd. - Enigma Diagnostics Ltd. - Epigenomics AG - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Gen-Probe, Inc. For more information visit http://www.researchandmarkets.com/research/xg...diagnostic
EXAS: 21.05 (+0.21), AFFX: 14.01 (+0.02), CPHD: 35.67 (-0.07)
Biomarkers Market - Advancements in Post Genomic Technologies & Increasing R&D Spending Driving Future Growth
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/bnmhqv/biomarkers) has announced the addition of the "Biomarkers Market: By Types & Application" report to their offering. Biomarkers are biological molecules which act as indicator of a particular disease state or pharmacological conditions. Advancement in post genomic technologies, increasing R&D spending and dynamic applications of biomarkers in medicine will drive the future market growth. The market for Biomarkers is classified into five categories based on: - Types - Application areas - Therapeutic segments - Products - End users Each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biomarkers market. The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers. The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biomarkers market and future opportunities that can propel the market. Companies Mentioned: - Qiagen NV - PerkinElmer, Inc - Merck & Co, Inc - Bio-Rad Laboratories - Enzo Biochem - EKF Diagnostics Holdings plc - Meso Scale Diagnostics, LLC - Singulex, Inc - BioSims Technologies - Cisbio Bioassays - Signosis, Inc - Roche Diagnostic Limited - Siemens Healthcare - Abbott Laboratories Inc - Thermo Fisher Scientific, Inc - Agilent Technologies Inc - Aushon BioSystem Inc - Epistem Ltd - GE Healthcare Inc - Beckman Coulter, Inc - Biomoda, Inc - Epigenomics AG Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Market Forces 5. Strategic Analysis 6. By Types 7. By Application 8. By Therapeutic areas 9. By Products 10. By End Users 11. Geographic Analysis 12. Market Entropy 13. Company profiles 14. Appendix For more information visit http://www.researchandmarkets.com/research/bnmhqv/biomarkers
ABT: 44.93 (-0.12), ENZ: 6.42 (-0.24), A: 48.10 (-0.03), MRK: 63.25 (-0.38), PKI: 54.40 (-0.32)
OTC Markets Group Announces First Quarter 2015 Performance of OTCQX and OTCQB Indexes, OTCM ADR Index and OTCQX30 Index and Quarterly Rebalancing
PR Newswire - Thu Apr 16, 3:30PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities, today announced the first quarter 2015 performance of the OTCQX® Indexes, the OTCQB® Composite Index, the OTCM QX ADR 30 Index ("OTCQX30"
and the OTCM ADR Index and the results of the quarterly re-balancing of the indexes.
World Cancer Diagnostic Testing Markets Report 2016
M2 - Wed Jan 20, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/xg6l8p/cancer_diagnostic) has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Partial List - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Ambrilia Biopharma, Inc. - AMDL, Inc. - Asuragen, Inc. - Aureon Laboratories, Inc. - Bard Diagnostics, Inc. - Beckman, Dickinson and Company (BD) Diagnostics - TriPath - Beckman Coulter, Inc. - Biocode S.A. - BioCurex - Biomedical Diagnostics - Biomerica - bioMerieux - BioModa, Inc. - Bruker Daltonics - Byk Gulden - Cepheid - Clarient, Inc. - Correlogic Systems, Inc. - CytoCore (formerly Molecular Diagnostics, Inc.) - Cytogen Corporation (now EUSA Pharma) - diaDexus, Inc. - DiagnoCure, Inc. - Diagnostic Automation / Cortez Diagnostics, Inc. - DRG International, Inc. - Eisai Co., Ltd. - Enigma Diagnostics Ltd. - Epigenomics AG - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Gen-Probe, Inc. For more information visit http://www.researchandmarkets.com/research/xg...diagnostic
EXAS: 21.05 (+0.21), AFFX: 14.01 (+0.02), CPHD: 35.67 (-0.07)
Biomarkers Market - Advancements in Post Genomic Technologies & Increasing R&D Spending Driving Future Growth
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/bnmhqv/biomarkers) has announced the addition of the "Biomarkers Market: By Types & Application" report to their offering. Biomarkers are biological molecules which act as indicator of a particular disease state or pharmacological conditions. Advancement in post genomic technologies, increasing R&D spending and dynamic applications of biomarkers in medicine will drive the future market growth. The market for Biomarkers is classified into five categories based on: - Types - Application areas - Therapeutic segments - Products - End users Each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biomarkers market. The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers. The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biomarkers market and future opportunities that can propel the market. Companies Mentioned: - Qiagen NV - PerkinElmer, Inc - Merck & Co, Inc - Bio-Rad Laboratories - Enzo Biochem - EKF Diagnostics Holdings plc - Meso Scale Diagnostics, LLC - Singulex, Inc - BioSims Technologies - Cisbio Bioassays - Signosis, Inc - Roche Diagnostic Limited - Siemens Healthcare - Abbott Laboratories Inc - Thermo Fisher Scientific, Inc - Agilent Technologies Inc - Aushon BioSystem Inc - Epistem Ltd - GE Healthcare Inc - Beckman Coulter, Inc - Biomoda, Inc - Epigenomics AG Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Market Forces 5. Strategic Analysis 6. By Types 7. By Application 8. By Therapeutic areas 9. By Products 10. By End Users 11. Geographic Analysis 12. Market Entropy 13. Company profiles 14. Appendix For more information visit http://www.researchandmarkets.com/research/bnmhqv/biomarkers
ABT: 44.93 (-0.12), ENZ: 6.42 (-0.24), A: 48.10 (-0.03), MRK: 63.25 (-0.38), PKI: 54.40 (-0.32)
OTC Markets Group Announces First Quarter 2015 Performance of OTCQX and OTCQB Indexes, OTCM ADR Index and OTCQX30 Index and Quarterly Rebalancing
PR Newswire - Thu Apr 16, 3:30PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities, today announced the first quarter 2015 performance of the OTCQX® Indexes, the OTCQB® Composite Index, the OTCM QX ADR 30 Index ("OTCQX30"
and the OTCM ADR Index and the results of the quarterly re-balancing of the indexes. 
